Who are Infliximab [infliximab biosimilar 3]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [89Zr]Zr-crefmirlimab berdoxam, Venetoclax; Rituximab, Hympavzi, Beyfortus, Darzalex, Praxbind.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/infliximab-infliximab-biosimilar-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Infliximab [infliximab biosimilar 3] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infliximab [infliximab biosimilar 3] (infliximab-infliximab-biosimilar-3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Oncology.

marketed monoclonal antibody tumor necrosis factor-alpha (TNF-alpha) Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Infliximab [infliximab biosimilar 3] (infliximab-infliximab-biosimilar-3) — Pfizer. Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Infliximab [infliximab biosimilar 3] TARGET	infliximab-infliximab-biosimilar-3	Pfizer	marketed	monoclonal antibody	tumor necrosis factor-alpha (TNF-alpha)
[89Zr]Zr-crefmirlimab berdoxam	89zr-zr-crefmirlimab-berdoxam	Pfizer	marketed	Radiolabeled Monoclonal Antibody	Fibroblast Activation Protein (FAP)	Not specified
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Hympavzi	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01
Beyfortus	NIRSEVIMAB	AstraZeneca	marketed	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]	RSV	2023-01-01
Darzalex	daratumumab	Johnson & Johnson	marketed	Monoclonal antibody	CD38	2015-01-01
Praxbind	IDARUCIZUMAB	Boehringer Ingelheim	marketed	Humanized Monoclonal Antibody Fragment [EPC]	dabigatran and its acylglucuronide metabolites	2015-01-01

Recent regulatory actions (last 90 days)

2026-04-07 — Beyfortus · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

Pfizer · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Celltrion · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Clinique des Céphalées de Montréal · 1 drug in this class
Dermira, Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gliknik Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Infliximab [infliximab biosimilar 3] — Competitive Intelligence Brief. https://druglandscape.com/ci/infliximab-infliximab-biosimilar-3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab